tbuckley/cabot-search huggingface dataset:
Treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) and cardiovascular disorders or diabetes: The Prostate Cancer Registry.
Authors: Nicolaas Lumen, Simon Chowdhury, Alison J. Birtle, Anders Bjartell, Luis Costa, Susan Feyerabend, Luca Galli, Ewa Kalinka-Warzocha, Gero Kramer, Pablo Maroto, Vsevolod B Matveev, Thomas Paiss, Salvatore Pisconti, Dominique Spaeth, Francisco Gomez Veiga, Laurent Antoni, Edwin Klumper, Robert Wapenaar, Florence Thoret-Bauchet, Emma Lee
Journal: Journal of Clinical Oncology (2017)

e16537 Background: The Prostate Cancer Registry is a prospective study of &gt;3000 men with mCRPC in routine care. These patients (pts) have a high level of comorbidities which are often underrepresented in RCTs. Methods: Data were collected from pts with mCRPC irrespective of treatment (tx). Outcomes in pts with comorbidities were assessed. Results: At study entry, 16.6% of pts had a cardiac disorder, 9.7% hypertension only, 17.7% diabetes. Characteristics, first txs and outcomes are shown in the table below. Conclusions: In this real-life setting, AAP, ENZ, or DOC tx was feasible in pts with cardiac disorders, hypertension or diabetes; proportions treated with each drug were similar to the overall mCRPC population. Regardless of tx PFS was shorter than TTP, which may reflect the impact of pts’ comorbidities in real life. Pts with cardiac disorders had poorer outcomes vs the overall population. Clinical trial information: NCT02236637. [Table: see text]
Trop-2 expression on treatment resistant cancer cells in castrate-resistant prostate cancer (CRPC) as a predictive biomarker for targeted therapy.
Authors: Kimberly Peihsi Ku, Joshua Michael Lang, Jamie Sperger, Scott Dehm, Manish Kohli, Liguo Wang, Liewei Wang, Scott T. Tagawa, Howard I. Scher
Journal: Journal of Clinical Oncology (2017)

5045 Background: Trophoblastic cell-surface antigen (Trop-2) is a transmembrane glycoprotein that is highly expressed in many solid tumors. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate of an anti-Trop-2 humanized antibody with SN-38. Early clinical trials have shown high response rates in a broad range of diseases including triple negative breast and urothelial cancers. We evaluated Trop-2 expression in tumor biopsies and circulating tumor cells (CTCs) from men with mCRPC (metastatic castrate-resistant prostate cancer). Methods: Trop-2 expression was evaluated from mCRPC biopsies from patients (Pts) treated with abiraterone acetate (AA) on the PROMOTE clinical trial, CTCs from a separate cohort treated with either enzalutamide or AA. Trop-2 CTCs were compared with EpCAM captured CTCs using a microscale technology termed the VERSA (Vertical Exclusion-based Rare Sample Analysis) platform to compare protein and gene expression signatures of resistance to these agents. Results: RNA sequencing identified Trop-2 gene expression in &gt; 70% of metastatic biopsies. The AR splice variant V7 was found in 48 biopsies that also expressed Trop-2. Trop-2 expression was not altered by treatment with AA at 12 weeks. The number of CTCs captured from 25 pts with Trop-2 or EpCAM were closely correlated (R 2 = 0.84). Gene expression analysis showed similar patterns of expression for the TROP-2 and EPCAM captured cells. AR splice variant expression (AR-V7, AR-V9) in Trop-2 and EpCAM CTCs was detected in 33% of patients. Expression of neuroendocrine markers was identified in 40% of Trop-2 CTCs. Conclusions: Trop-2 is frequently expressed in mCRPC and co-expressed in tumors that express AR splice variants. Trop-2 CTCs are detected in CRPC pts previously treated with AA or Enzalutamide that also express multiple AR splice variants and neuroendocrine markers. The results support Trop-2 expression as predictive biomarker of sensitivity to targeted therapies tumors resistant to AA or Enzalutamide. Men with mCRPC are being enrolled on a Phase I trial with IMMU-132, and multi-site Phase II clinical trial in men who have progressed on AA or Enzalutamide is being finalized.
GW28-e0055 The Management Manner and Reasons Analysis for Stress-induced Hypertension in Adults with Aortic Dissection (Stanford type A) after Bentall or Improved-Cabrol of Cardiac Surgery
Authors: Zheng Jia, Qian Liu, Zhengjiang Xing, Honglin Zou, Chuncheng Li, Yaxiong Li, Fandi Meng, Jie Wei
Journal: Journal of the American College of Cardiology (2017)
Recomendações europeias para o controlo e a prevenção da doença dos legionários associada a viagens: a experiência italiana
Authors: M C Rota, M R Caporali, M Massari
Journal: Eurosurveillance (2004)

Em Italia, foram identificados 35 clusters de doenca dos legionarios associados a viagens entre Julho de 2002, data da adopcao das recomendacoes europeias sobre a vigilância da doenca dos legionarios pela rede EWGLINET, e Outubro de 2003. Oito (28,6%) deles nao teriam sido detectados sem a existencia desta rede. 
Os clusters identificados eram pequenos com dois a seis casos, e representavam um total de 87 doentes. Foram implicados cinco parques de campismo e 30 hoteis/residenciais. O diagnostico, confirmado para 92,0% dos casos, foi realizado principalmente por deteccao da antigenuria na urina (84,7%). So um caso resultou no isolamento de uma estirpe clinica. 
Em todos os 35 clusters identificados foram realizadas investigacoes ambientais, as quais resultaram em amostras dos sistemas hidricos implicados. em 23 dos 35 clusters (65,7%) investigados identificou-se Legionella pneumophila. Em 15 dos 35 locais implicados, as investigacoes ja tinham comecado no momento da notificacao dos clusters ao EWGLI. Isto deve-se ao facto de em Italia realizar-se uma investigacao ambiental completa depois da declaracao de qualquer caso, mesmo que isolado. Medidas de controlo foram implementadas em todos os locais de risco e apenas um hotel foi fechado. 
Para os 35 clusters, os relatorios foram concluidos e enviados atempadamente, demonstrando que e possivel respeitar os procedimentos exigidos pelas recomendacoes europeias.
All-in-one RNA-based assay to detect therapeutic biomarkers in lung cancer
Authors: J. Wei, A. Rybczynska, A. van der Wekken, A. Saber, M. Terpstra, E. Schuuring, W. Timens, T. Hiltermann, H. Groen, A. van den Berg, K. Kok
Journal: Annals of Oncology (2017)
Geographic Diffusion and Implementation of Acute Care Surgery
Authors: Jasmine A. Khubchandani, Angela M. Ingraham, Vijaya T. Daniel, Didem Ayturk, Catarina I. Kiefe, Heena P. Santry
Journal: JAMA Surgery (2017)

Owing to lack of adequate emergency care infrastructure and decline in general surgery workforce, the United States faces a crisis in access to emergency general surgery (EGS) care. Acute care surgery (ACS), an organized system of trauma, general surgery, and critical care, is a proposed solution; however, ACS diffusion remains poorly understood.To investigate geographic diffusion of ACS models of care and characterize the communities in which ACS implementation is lagging.A national survey on EGS practices was developed, tested, and administered at all 2811 US acute care hospitals providing EGS to adults between August 2015 and October 2015. Surgeons responsible for EGS coverage at these hospitals were approached. If these surgeons failed to respond to the initial survey implementation, secondary surgeons or chief medical officers at hospitals with only 1 general surgeon were approached.Survey responses on ACS implementation were linked with geocoded hospital data and national census data to determine geographic diffusion of and access to ACS.We measured the distribution of hospitals with ACS models of care vs those without over time (diffusion) and by US counties characterized by sociodemographic characteristics of county residents (access).Survey response rate was 60% (n = 1690); 272 responding hospitals had implemented ACS by 2015, steadily increasing from 34 in 2001 to 125 in 2010. Acute care surgery implementation has not been uniform. Rural regions have limited ACS access, with hospitals in counties with greater than the 75th percentile population having 5.4 times higher odds (95% CI, 1.66-7.35) of implementing ACS than hospitals in counties with less than 25th percentile population. Communities with greater percentages of adults without a college degree also have limited ACS access (OR, 3.43; 95% CI, 1.81-6.48). However, incorporating EGS into ACS models may be a potential equalizer for poor, black, and Hispanic communities.Understanding and addressing gaps in ACS implementation across communities will be crucial to ensuring health equity for US residents experiencing general surgery emergencies.
Survival and safety of atezolizumab by best overall response (BOR) in the phase III NSCLC OAK study
Authors: F. de Marinis, F. Barlesi, A. Rittmeyer, J. von Pawel, J.-Y. Han, M. Kozloff, A. Spira, L. Fehrenbacher, D.R. Gandara, W. Yu, P. He, C. Yun, M. Ballinger, M. Gandhi, S. Gadgeel
Journal: Annals of Oncology (2017)
HELICS: a European project to standardise the surveillance of hospital acquired infection, 1994-1995
Authors: R Mertens, J. M.J van den Berg, J Fabry, O. B Jepsen
Journal: Eurosurveillance (1996)

During the 1990s several European countries began to set up national or regional networks for the surveillance of hospital acquired infections. Most of these networks were based on the US Centers for Disease Control and Prevention (CDC) National Nosocomia
Eribulin is safe and efficient in metastatic breast cancer in elderly patients. Results from the REPROLINE multicentric retro-prospective cohort
Authors: J. Martin-Babau, M. Robert, V. Seegers, M-J. Paillard, X. Pivot, C. Gourmelon, L. Uwer, C. Korenbaum, T. Petit, J-C. Thery, M. Som, C. Lefeuvre-Plesse, C. Perret, H. Simon, A-C. Hardy-Bessard, H. Desclos, H. Bourgeois, M. Campone, O. Tredan, A. Patsouris
Journal: Annals of Oncology (2017)
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
Authors: Ari J Green, Jeffrey M Gelfand, Bruce A Cree, Carolyn Bevan, W John Boscardin, Feng Mei, Justin Inman, Sam Arnow, Michael Devereux, Aya Abounasr, Hiroko Nobuta, Alyssa Zhu, Matt Friessen, Roy Gerona, Hans Christian von Büdingen, Roland G Henry, Stephen L Hauser, Jonah R Chan
Journal: The Lancet (2017)
Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.
Authors: Graeme Fraser, Paula Cramer, Fatih Demirkan, Rodrigo Santucci Silva, Halyna Pylypenko, Sebastian Grosicki, Ann Janssens, Aleksander Pristupa, Jiri Mayer, Marie-Sarah Dilhuydy, Javier Loscertales, Andre Goy, Abraham Avigdor, Simon Rule, Charles Phelps, Michelle Mahler, Mariya Salman, Angela J. Howes, Sriram Balasubramanian, Asher Alban Akmal Chanan-Khan
Journal: Journal of Clinical Oncology (2016)

7525 Background: The phase 3 HELIOS study evaluated I + BR vs placebo (P) + BR in patients (pts) with previously treated CLL/SLL. At first analysis (median follow-up: 17.0 months) progression-free survival (PFS) was significantly improved for I + BR vs P + BR (HR [95% CI]: 0.203 [0.15-0.28], p< 0.0001). Prior studies have shown deepening responses with continued ibrutinib treatment; long-term follow-up assessing durability and depth of response is important. Methods: 578 pts received BR (≤ 6 cycles) and were randomized 1:1 to I (420 mg daily) or P (N = 289/arm). Pts with del17p (≥ 20% of cells) were excluded. Primary end point was PFS. Key secondary end points: overall survival (OS), overall response rate (ORR), and rate of minimum residual disease negative (MRD -ve) response. Results: Median follow up is 25.4 months. I + BR continues to show improvement in PFS vs P + BR (investigator [INV]-assessed median: not reached [NR] vs 14.2 months; HR [95% CI]: 0.199 [0.15, 0.26], p < 0.0001; 2-yr rate: 74.8% vs 20.9%). Median OS is still NR in either arm (HR [95% CI]: 0.670 [0.44, 1.02], p = 0.0587; 2-yr rate: 86.2% vs 81.5%); 142 pts (49.1%) in the P + BR arm with confirmed PD have crossed over to receive I, as permitted by protocol. The updated INV-assessed ORR is 87.2% for I + BR vs 66.1% for P + BR (p < 0.0001); updated rates of CR/CRi are 33.9% vs 7.2% (rates at first analysis: 21.4% vs 5.9%). Rates of MRD -ve response for the intent-to-treat population are 18.0% (52/289) for I + BR and 4.8% (14/289) for P + BR (p < 0.0001) (rates at first analysis: 12.8% vs 4.8%). Median PFS2 is unreached in both arms, but PFS2 is significantly longer for pts assigned to I + BR vs P + BR, despite crossover (HR [95% CI]: 0.622 [0.42, 0.92], p= 0.0162). Safety is consistent with first analysis. Conclusions: I + BR continues to demonstrate superiority vs P + BR with significantly longer PFS and higher ORR. Responses continue to deepen with continuous ibrutinib therapy with rates of CR/CRi and MRD -ve response increasing over time. At every MRD level (<0.01% or ≥10% CLL+), I + BR showed a more sustained PFS than P + BR. These 2-year follow-up data confirm the important role of ibrutinib in pts with previously treated CLL. Clinical trial information: NCT01611090.
The FAST Examination for Children With Abdominal Trauma
Authors: Jennifer R. Marin, J. Matthew Fields, Vivek S. Tayal
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intratumoral heterogeneity of SMAD4 immunohistochemical (IHC) expression and its role in prediction of recurrence patterns in patients with resectable pancreatic cancer (PC)
Authors: I. Pokataev, A. Kudaibergenova, A. Artemyeva, D. Podluzhnyi, N. Kudashkin, Y. Patyutko, E. Moroz, E. Kharchenko, A. Popova, M. Fedyanin, A. Rumyantsev, I. Bazin, A. Tryakin, E. Glukhov, O. Sekhina, D. Chekini, S. Tjulandin
Journal: Annals of Oncology (2017)
High-dose versus low-dose cisplatin with definitive concurrent radiotherapy for squamous cell carcinoma of the head and neck (SCC): An analysis of veteran’s health registry data
Authors: J. Bauml, R. Vinnakota, Y-H.A. Park, S.E. Bates, T. Fojo, C. Aggarwal, S. Lunate, N. Damjanov, R. Mamtani, C.J. Langer, R.B. Cohen, K. Sigel
Journal: Annals of Oncology (2017)
Abstract 17985: Natural History of Uncomplicated Stanford Type B Aortic Dissection and Intramural Hematoma
Authors: Anna M Sailer, Patricia J Nelemans, Sander M van Kuijk, Anne S Chin, Aya Kino, Peter Chiu, Mark Huining, Michael P Fischbein, Michael D Dake, D. C Miller, Geert W Schurink, Dominik Fleischmann
Journal: Circulation (2016)

Background: Survivors of uncomplicated Stanford type-B aortic lesions treated with optimal medical therapy (OMT) are at high risk for aneurysm degeneration and late complications. The rate of false...
Long-term follow-up results of stage III-IV non-small-cell lung cancer (NSCLC) patients treated with an epitope derived from Indoleamine 2,3 Dioxygenase (IDO) in a phase I study
Authors: J.W. Kjeldsen, T.Z. Iversen, L.E. Noerregaard, A. Mellemgaard, M.H. Andersen, I-M. Svane
Journal: Annals of Oncology (2017)
Percutaneous cecostomy with fully covered self-expandable metal stent for initial management of severe malignant colon obstruction
Authors: Chin Lim, Nicholas McDonald, Martin Freeman, Stuart Amateau
Journal: Endoscopy (2017)

Traditionally, catheter-based percutaneous cecostomy has been utilized in the setting of closed-looped colonic obstruction and in selected patients with fecal incontinence in whom conservative management has failed. Although the procedure is associated with high rates of technical success, complications including catheter migration or dislodgement are common and occur in up to a third of patients. Catheter occlusion and leakage from the catheter site are also common, with leakage often occurring on the skin (20 %) or within the peritoneum (12 %) [1] [2] [3] [4] [5]. Here, we explored the option of using a percutaneous, fully covered, self-expandable, metal stent (FCSEMS) for sequential decompression following malfunction of a percutaneous catheter. In theory, the caliber of the stent would allow improved drainage, while the external flange could be secured with a suture, reducing the risk of migration or dislodgement.
Tablets of paliperidone using compression-coated technology for controlled ascending release
Authors: Yingying Tang, Huan Teng, Yanan Shi, Haibing He, Yu Zhang, Tian Yin, Cuifang Cai, Xing Tang
Journal: Asian Journal of Pharmaceutical Sciences (2017)

The aim of this work was to prepare ascending release compression-coated (CC) tablets with paliperidone (PAL) using a simple manufacturing technique and short manufacturing process. The release behavior and mechanisms in vitro of the final tablets was investigated and evaluated. The PAL CC tablets were comprised of a core layer of high viscosity hydroxypropyl cellulose (HPC-H) and a coating layer of high viscosity hydroxypropyl methylcellulose (HPMC-K100M). Several factors such as materials and core tablet compositions were studied for their influence in the formulation procedure. The drug release mechanism was studied using gravimetric analysis. The data could be fitted to the Peppas model. The ascending drug release results were expressed in terms of the slope of the release curve at different time points. Results showed that the formulation could achieve a good ascending drug release when the weight ratio of PAL was 5:1 (core:layer). The fraction of HPC and HPMC was 33 %, and the combination of Eudragit RL-PO was 10%. The ascending release mechanism was due to solvent penetration into the PAL CC tablets, and subsequent drug dissolution from the gelatinous HPC and HPMC matrix erosion. The release mechanism was therefore a combination of diffusion and erosion. This work demonstrated that the compression-coated tablets could achieve controlled ascending release over 24 h for the oral administration systems.
Prevalence of human cytomegalovirus congenital infection in Portuguese newborns
Authors: P Paixão, S Almeida, P Gouveia, L Vilarinho, R Vaz Osório
Journal: Eurosurveillance (2009)

Human cytomegalovirus (HCMV) is considered the most frequent cause of congenital infection, occurring in 0.2 to 2.2% of all live births. Since this is a wide range of prevalences observed in different studies, it would be desirable to investigate the prevalence of this infection at national level. The aim of this study was the evaluation of the national prevalence of HCMV congenital infection. We analysed a total of 3,600 Guthrie cards collected from Portuguese newborns during a period of 14 months (August 2003 to September 2004). The cards covered all regions of Portugal and were proportional to the number of births in each region. A heat DNA extraction method was used, followed by DNA amplification by nested PCR. Sensitivity and specificity of this method were evaluated as 93% and 100%, respectively, using 28 cards from HCMV-positive and 280 cards from HCMV-negative children. The national prevalence of congenital HCMV was determined as 1.05% (95% confidence interval: 0.748-1.446). This is the first study of the prevalence of HCMV congenital infection at national level in Portugal. It suggests that Portugal may have one of the highest prevalences of congenital HCMV infection in Europe.
GW28-e0696 Associations of Serum High-Density Lipoprotein Cholesterol with Atherosclerosis Cardiovascular and Cancer Occurrence Among Chinese in Kailuan Cohort
Authors: Xumin Guan, Xiao Lei Yang, Yi Heng Yang, Xin Tao Li, Khalid BinWaleed, Rong Feng Zhang, Xiang Gao, Si Yan Zhan, Ying Liu, Hui Hua Li, Shou Ling Wu, Yun Long Xia
Journal: Journal of the American College of Cardiology (2017)
Successful transdermal allergen delivery and allergen-specific immunotherapy using biodegradable microneedle patches
Authors: Ji Hye Kim, Jung U. Shin, Seo Hyeong Kim, Ji Yeon Noh, Hye Ran Kim, Jungsoo Lee, Howard Chu, Kyoung Yong Jeong, Kyung Hee Park, Jung Dong Kim, Hong Kee Kim, Do Hyeon Jeong, Tai-Soon Yong, Jung-Won Park, Kwang Hoon Lee
Journal: Biomaterials (2017)
Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement
Authors: Arunabh Talwar, Joe G. N. Garcia, Halley Tsai, Matthew Moreno, Tim Lahm, Roham T. Zamanian, Roberto Machado, Steven M. Kawut, Mona Selej, Stephen Mathai, Laura Hoyt D’Anna, Sonu Sahni, Erik J. Rodriquez, Richard Channick, Karen Fagan, Michael Gray, Jessica Armstrong, Josanna Rodriguez Lopez, Vinicio de Jesus Perez
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Health disparities have a major impact in the quality of life and clinical care received by minorities in the United States. Pulmonary arterial hypertension (PAH) is a rare cardiopulmonary disorder that affects children and adults and that, if untreated, results in premature death. The impact of health disparities in the diagnosis, treatment, and clinical outcome of patients with PAH has not been systematically investigated.The specific goals of this research statement were to conduct a critical review of the literature concerning health disparities in PAH, identify major research gaps and prioritize direction for future research.Literature searches from multiple reference databases were performed using medical subject headings and text words for pulmonary hypertension and health disparities. Members of the committee discussed the evidence and provided recommendations for future research.Few studies were found discussing the impact of health disparities in PAH. Using recent research statements focused on health disparities, the group identified six major study topics that would help address the contribution of health disparities to PAH. Representative studies in each topic were discussed and specific recommendations were made by the group concerning the most urgent questions to address in future research studies.At present, there are few studies that address health disparities in PAH. Given the potential adverse impact of health disparities, we recommend that research efforts be undertaken to address the topics discussed in the document. Awareness of health disparities will likely improve advocacy efforts, public health policy and the quality of care of vulnerable populations with PAH.
Is It Ethically Acceptable to Screen Patients for Obstructive Sleep Apnea and Not Offer Them Positive Air Pressure Therapy in a Clinical Trial?
Authors: Jennifer B. McCormick, Joel T. Wu, Adelaide Doussau
Journal: The American Journal of Bioethics (2017)

"Is It Ethically Acceptable to Screen Patients for Obstructive Sleep Apnea and Not Offer Them Positive Air Pressure Therapy in a Clinical Trial?." The American Journal of Bioethics, 17(10), pp. 76–77
Practical screening system of oncogenic driver fusions in lung adenocarcinoma, using the NanoString nCounter
Authors: K. Takamochi, Y. Suehara, F. Takahashi, K. Mogushi, S. Kohsaka, H. Mano, K. Takeuchi, T. Saito, T. Hayashi, K. Takahashi, K. Suzuki
Journal: Annals of Oncology (2017)